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Disopyramide (DP), mexiletine (MX), and ﬂecainide (FL) are class I antiarrhythmic drugs.
However, these drugs exert diﬀerent eﬀects on the electrocardiogram (ECG) based on their
unique actions on cardiac myocytes. The electrocardiographic changes during combination
therapy with these drugs are not well understood. The purpose of the present study was to
evaluate acute morphologic changes in the ECG based on signal-averaged high resolution
ECG (SAECG) after administration of the drugs in relation to their antiarrhythmic eﬃcacy
and safety. Twenty-one patients with frequent and stable premature ventricular contractions
(PVC) were studied. Changes in the ﬁltered QRS duration (f-QRS) and the root mean square
voltage of the last 40msec of the QRS complex (RMS40) were evaluated. Suppression of
PVCs was achieved soon after intravenous administration of the drugs (63% for DP, 43% for
MX, 86% for FL and 100% for DP+MX). Although DP and FL signiﬁcantly prolonged
f-QRS, MX had little eﬀect on f-QRS. DP+MX also prolonged f-QRS, but the degree of
prolongation was moderate. RMS40 was signiﬁcantly decreased by DP and FL, but not by
MX. DP+MX also decreased RMS40, but the decrease was less than for DP alone. Late
potentials were observed after administration in 56% of patients with DP, 0% with MX, 67%
with FL and 0% with DP+MX. No adverse events were reported during the study.
In summary, the class I antiarrhythmic drugs exerted diﬀerent acute eﬀects on SAECG
parameters. The combination of DP and MX increased the eﬃcacy on suppressing PVC
without excess additive changes on SAECG parameters. We conclude that combination
therapy with DP and MX is eﬃcacious and safe in patients with PVC and the analysis of
SAECG during antiarrhythmic therapy is clinically important.
(J Arrhythmia 2006; 22: 155–160)
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Introduction
Sodium channel blocking agents, known as class I
antiarrhythmic drugs,1) are being used worldwide as
the ﬁrst-line therapy for various clinical arrhythmias.
These drugs have potential eﬀects on the electro-
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cardiogram (ECG) as a reﬂection of their antiar-
rhythmic action or sometimes as an adverse proar-
rhythmic action. It is thought that these eﬀects de-
pend on their cellular electrophysiologic properties.
Class I antiarrhythmic drugs usually are divided
into three subgroups; Ia, Ib and Ic,2) and disopyr-
amide (DP), mexiletine (MX), and ﬂecainide (FL)
are representative drugs of each respective subgroup.
Based on their separate modes of action on cardiac
myocytes, these drugs exert diﬀerent eﬀects on the
electrocardiogram (ECG). Speciﬁcally, DP prolongs
QRS duration and QT interval, MX has almost no
eﬀect, and FL mainly prolongs QRS duration.3,4)
However, the electrocardiographic changes during
combination therapy with these drugs are not well
understood.
The purpose of the present study was to evaluate
acute morphologic changes of the ECG using signal-
averaged high resolution ECG (SAECG) after
administration of these drugs individually or in
combination in relation to their antiarrhythmic
eﬃcacy and safety.
Patients and Methods
Patients
Twenty-one adult patients of medium build were
enrolled in this study. All patients had >5/min
stable premature ventricular contractions (PVC).
Repeated Holter ambulatory monitoring recordings
conﬁrmed the appearance of PVC. All the PVCs
were monomorphic and isolated during the study.
None of the patients had organic heart disease or
congestive heart failure. Informed consent was
obtained from all patients before the study.
Administration of Antiarrhythmic Drugs
All antiarrhythmic drugs were given intravenously
based on the following protocols:
. disopyramide (DP) 100mg/5min, n ¼ 19
. mexiletine (MX) 125mg/5min, n ¼ 21
. ﬂecainide (FL) 75mg/5min, n ¼ 7
Combination therapy was given in 7 patients who
did not achieve suﬃcient suppression of PVC by DP
alone or MX alone using the following protocol:
. DP+MX MX 125mg/5min immediately fol-
lowed by DP 100mg/5min, n ¼ 7
Each drug regimen was performed with a 1 or 2
week interval between regimens.
Evaluation of Antiarrhythmic Efﬁcacy
We considered that a drug was ‘‘eﬀective’’ when a
>75% reduction of the number of PVC was obtained
from 5min to 20min after the end of injection. The
surface ECG was monitored continuously through-
out the study.
Recording and Measurement of SAECG
SAECG was recorded immediately before and
after each drug administration using an NEC-SANEI
signal processor 7T18. On each occasion, more than
200 consecutive sinus beats were averaged to obtain
a low-noise recording for the following measure-
ments. The ﬁltered QRS duration (f-QRS) and the
root mean square voltage of the last 40msec of the
QRS complex (RMS40) were measured automati-
cally for the averaged signals according to Simson’s
methods.5) A late potential (LP) was deﬁned as
‘‘positive’’ when the f-QRS was more than 120msec
based on the criterion of Gomes et al.6)
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Figure 1 Antiarrhythmic eﬃcacy against
PVC.
DP: disopyramide, MX: mexiletine, FL: ﬂecai-
nide.
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Results
Antiarrhythmic Efﬁcacy for PVC
Rates of response for each drug are shown in
Figure 1. Acute suppression of PVC was achieved in
12 of 19 patients (63%) with DP, 9 of 21 (43%) with
MX, and 6 of 7 (86%) with FL. Combination therapy
with DP+MX, tested only in patients who did not
respond to DP or MX alone, increased the antiar-
rhythmic eﬃcacy, resulting in perfect suppression (7
of 7; 100%).
None of the patients had any worsening of PVC
frequency or nature throughout the study.
Changes in f-QRS Immediately after Drug Ad-
ministration
DP and FL both signiﬁcantly prolonged f-QRS,
but MX had almost no eﬀect as shown in Figure 2A,
B, C (DP: 107:5 11:4! 122:6 14:3msec; p <
0:0001, MX: 109:7 14:6! 110:9 14:6msec;
p < 0:05, FL: 106:5 13:3! 126:9 16:8msec;
p < 0:005). Combination therapy with DP+MX also
signiﬁcantly prolonged f-QRS. However, the magni-
tude of the change was less than that with DP alone
as shown in Figure 3 (DP: 16:4 4:7%, MX: 1:2
1:9%, DP+MX: 12:3 7:3%, DP vs. MX; p <
0:0001, MX vs. DP+MX; p < 0:002, DP vs. DP+
MX; p < 0:05, respectively).
Changes of RMS40 Immediately after Drug
Administration
As shown in Figure 4A, B, C, DP and FL markedly
decreased RMS40 in all patients (DP: 13:0
11:1! 7:7 7:9 microvolt; p < 0:0001, FL:
14:9 12:5! 6:3 6:5 microvolt; p < 0:02, for
all). MX did not exert uniform eﬀects on RMS40,
resulting in almost no change in the mean value
(MX: 11:1 11:2! 9:9 11:4 microvolt; n.s.).
Though DP+MX also signiﬁcantly decreased
RMS40, the change was less than that with DP
alone (DP: 49:4 15:9%, MX: 13:0 15:7%,
DP+MX: 29:6 26:9%, DP vs. MX; p < 0:0001,
MX vs. DP+MX; n.s., DP vs. DP+MX; p < 0:01;
Figure 5).
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Figure 2 F-QRS before and after drug administration.
f-QRS: ﬁltered QRS duration (msec). A. DP: disopyramide. B. MX: mexiletine. C. FL: ﬂecainide.
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Figure 3 Comparison of percent change in the f-QRS
between single drug and combination therapy.
f-QRS: ﬁltered QRS duration, DP: disopyramide, MX: mexiletine,
DP+MX: combination therapy with DP and MX.
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LP Evaluation
The LP was positive in 2 of 21 patients. But it
became positive after administration of drugs in 10
(56%) of 18 patients receiving DP, 0 (0%) of 19
patients receiving MX, 4 (67%) of 6 patients
receiving FL, and 0 (0%) of 6 patients receiving
DP+MX. Thus, combined use of DP and MX
diminished the eﬀect on conduction delay without
weakening antiarrhythmic eﬃcacy on suppressing
PVCs.
Discussion
Inﬂuence of Individual Antiarrhythmic Drugs on
SAECG Parameters
Changes in f-QRS and RMS40 after the admin-
istration of class I antiarrhythmic drugs reﬂect the
diﬀerential mechanism of actions on the Na channel
for each drug.3) Since DP has a slow kinetic nature
and FL has a very slow kinetic nature in combining
with and dissociating from Na channels, they exert
strong Na channel blocking action not only at high
heart rates but also at low heart rates.7) Blockade of
Na channels reduces the rate of rise and amplitude of
the action potential, resulting in a depression in the
conduction velocity from cell to cell. This must
inﬂuence the duration of the QRS complex, although
the changes may be trivial. As a result, signiﬁcant
prolongation of the f-QRS and a decrease in the
RMS40 occur even in sinus rhythm.
In contrast, MX has almost no eﬀect on these
parameters. This can be explained by the fact that
MX is a fast kinetic drug. Since MX is thought to
dissociate very rapidly from Na channels, it may not
have enough time to eﬀect the ECG during sinus
beats, which have relatively slow rates.
In the clinical setting, we occasionally ﬁnd that
the QRS width on the surface ECG is often widened
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Figure 4 RMS40 before and after drug administration.
RMS40: root mean square voltage during last 40msec (microvolt). A. DP: disopyramide. B. MX: mexiletine. C. FL: ﬂecainide.
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Figure 5 Comparison of percent changes in the RMS40
between single drug and combination therapy.
RMS40: root mean square voltage during last 40msec (microvolt),
DP: disopyramide, MX: mexiletine, DP+MX: combination
therapy with DP and MX.
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during long-term treatment by class Ia or Ic drugs,
including DP or FL, but not widened by class Ib
drugs, like MX or lidocaine. The present study may
support this clinical observation from another point
of view based on SAECG, although we were
evaluating acute eﬀects of the drugs.
Effects of Combination Therapy with DP+MX on
SAECG Parameters
DP blocks Na channels in the activated state with
a slow kinetic nature. In contrast, MX exerts its Na
channel blocking action in the inactivated state with
a fast kinetic nature.8) Since their Na channel
blocking actions are complementary, they may have
additive or synergistic eﬀects when DP and MX are
used concomitantly.9)
Previous reports have described combination
therapy with class Ia and class Ib agents10,11) and
most of these reports indicate the superiority of these
combination therapies.12–14) DP+MX is one of the
most frequently used combination. The present study
also clearly showed the synergistic eﬀect of DP+
MX in treating PVC.
It is believed that a main part of the antiarrhythmic
action may come from the suppression of Na
channels in ventricular myocytes. A stronger and/
or wider spectrum of Na channel suppression can
increase the antiarrhythmic eﬃcacy in the clinical
setting, in which the state of the Na channels may be
inhomogeneous and unstable in the diseased heart.
As stated above, class Ia or Ic drugs deﬁnitely
change SAECG parameters. Since LP, which is one
of the most powerful predictors of severe ventricular
arrhythmias, is deﬁned as ‘‘positive’’ with a wide
f-QRS and low RMS40,5,15–17) an excess prolonga-
tion of f-QRS and/or an extreme decrease in the
RMS40 may be related to the arrhythmogenicity.
From a clinical point of view, excess changes in
SAECG parameters (a prolongation of f-QRS with a
decrease of RMS40) make the LP positive and may
lead to the appearance of arrhythmias because the
impulse conduction becomes slower or more in-
homogeneous.18) Fortunately, we never found any
worsening of arrhythmias or new severe arrhythmias
in our study, but the change in the LP from negative
to positive occurred in 56% of patients receiving DP
and in 67% of patients receiving FL. However, it
occurred in 0% of patients during combination
therapy with DP+MX in our series. Although DP+
MX also prolonged the f-QRS and decreased
RMS40, the magnitude of those changes with DP+
MX was much smaller than those with DP alone.
The change after DP+MX was never additive or
even signiﬁcantly reductive. In other words, DP+
MX exerted a protective eﬀect against proarrhyth-
mias, which should be avoided. This fact supports
the safety of the combination therapy.19,20)
Study Limitations
This study was designed to evaluate short-term
changes in SAECG parameters immediately after
administration of antiarrhythmic drugs. We do not
know whether similar changes may occur during
long-term use of these drugs in the clinical setting.
Since we used ﬁxed doses of each drug to simplify
the study protocol, no correction of the doses per
body weight was performed. Body weights of all the
patients were within a normal range. Although we
did not check the serum concentration of these drugs,
we believe that the concentrations were within the
clinically-eﬀective range during the study in each
case. The changes of SAECG parameters at several
lower doses of drugs should be checked to know a
cut-oﬀ-point from receiver operating characteristic
curve.
Another limitation of the present study is that
patients were not randomized. The number of the
patients in this study is small because patients who
have stable and reproducible PVC for hours to days
are quite rare in a single institution. Further objective
evaluation with large-scale multicenter trials will be
needed.
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